Percheron Therapeutics
- Short interest
- 0.02%
- −0.14 pp 30d
- as of 21 Feb 2025
- Reported shorts
- 237.1K
- Shares on issue
- 1.087B
Percheron Therapeutics (PER) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $147.3KM (source: ASX (Markit))vs $371.1KM (source: ASX (Markit)) (FY25)
- ASX (Markit), as at 14 Oct 2026
- NPAT
- −$4.8Mvs −$14.9M (FY25)
- Yahoo Finance, as at 14 Oct 2026
- EPS (diluted)
- −$0.004T (source: Derived: trailing 12 months at year end)vs −$0.014 (FY25)
- Derived: trailing 12 months at year end, as at 14 Oct 2026
- Rev YoY
- −60.3%FY
- EPS YoY
- n/aTTM
- ASX (Markit)
- Derived: trailing 12 months at year end
Summary of Appendix 4E and Annual Report, 19 Aug 2026
Percheron Therapeutics reported a statutory net loss of $4.8 million for FY2026, a 68% improvement from the prior year's $14.9 million loss, driven by reduced R&D spending and non-cash expenses. No dividends were declared. The company is advancing its oncology drug HMBD-002 (minperstobart) toward a Phase II trial in 2H CY2026, with new CEO Dr Michael Baker appointed to lead the next stage.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 14 Oct 2026
- Gross margin
- n/a
- Operating margin
- −3,816.4%
- Net margin
- −3,253.9%
- FCF margin
- −5,466.4%
- ROE
- −54.7%
- ROA
- −46.4%
- FCF conversion
- n/a
- Net cash (excl. leases)
- $4.1M
- Net debt / EBITDA
- n/a
- Current ratio
- 7.6×
- Interest cover
- −366.3×
- Cash dividends paid / net profit
- n/a
- Market cap
- $4.6M
- P/E
- n/a
- P/B
- 0.6×
Ratios use the reporting currency (AUD); market cap is in AUD. Sources: Yahoo Finance and ASX (Markit), as at 14 Oct 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $147.3KM (source: ASX (Markit)) | $371.1KM (source: ASX (Markit)) | $615.5KM (source: ASX (Markit)) | $384.9KM (source: ASX (Markit)) |
| Operating income | −$5.6M | −$16.7M | −$14.9M | −$13.3M |
| EBITDA | −$4.6M | −$14.8M | −$11.8M | −$11.3M |
| EBIT | −$4.8M | −$14.9M | −$11.9M | −$11.4M |
| Interest expense | $15.3K | $14.9K | $3.6K | $8.2K |
| Pretax income | −$4.8M | −$14.9M | −$11.9M | −$11.4M |
| Tax | $0 | $0 | $0 | $0 |
| NPAT | −$4.8M | −$14.9M | −$11.9M | −$11.4M |
| Net interest income | $131.9K | $356.2K | $611.9K | $376.8K |
| EPS basic | −$0.004T (source: Derived: trailing 12 months at year end) | −$0.014 | −$0.013 | −$0.017 |
| EPS diluted | −$0.004T (source: Derived: trailing 12 months at year end) | −$0.014 | −$0.013 | −$0.017 |
| Shares | 1.52B | 1.12B | 925.6M | 687.2M |
- ASX (Markit)
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- Appendix 4E and Annual ReportAnnual Results19 Aug 2026via asx_announcements
- Appendix 4E and Annual ReportAnnual Results19 Aug 2026via asx_announcements
- Quarterly Activities Report and Appendix 4CQuarterly Report31 Jul 2026via asx_announcements
- Quarterly Activities Report and Appendix 4CQuarterly Report30 Apr 2026via asx_announcements
- Half Yearly Report and AccountsHalf Year Results26 Feb 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Jan 2026via asx_announcements
- Quarterly Activities Report and Appendix 4CQuarterly Report31 Oct 2025via asx_announcements
- Appendix 4E and Annual ReportAnnual Results28 Aug 2025via asx_announcements
- Quarterly Activities Report and Appendix 4CQuarterly Report31 Jul 2025via asx_announcements
- Quarterly Activities Report and Appendix 4CQuarterly Report30 Apr 2025via asx_announcements
Showing 10 of 93 reports